GW Pharmaceutical Gets Closer To Forcing FDA On Cannabis

Forbes, 28 September 2016
Author: Debra Borchardt
“British biotech company GW Pharmaceuticals announced positive results on its latest Phase 3 clinical trial for its drug Epidiolex. The drug is cannabidiol-based and is used to treat children with Lennox-Gastaut syndrome, a rare form of childhood epilepsy. The next step for GW Pharmaceuticals is to seek approval from the U.S. Food and Drug Administration or FDA for approval. If approved, it would be the first plant-derived cannabinoid drug in the U.S. to be approved.”
Find article here.